公开(公告)号：US20190040473A1

公开(公告)日：2019-02-07

申请号：US16155220

申请日：2018-10-09

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Young-Deug KIM ,  En Sel OH ,  Jun Young CHOI ,  Sang Rea CHO

IPC: C12Q1/6886

Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.

公开(公告)号：US20190352703A1

公开(公告)日：2019-11-21

申请号：US16304340

申请日：2017-05-25

Applicant: GENCURIX INC.

Inventor： Young Kee SHIN ,  Bohyun BYUN ,  Hyunjeung CHOI ,  Joon Seok CHOI ,  Young Ho MOON ,  Jong Heun LEE ,  Sang Rea CHO ,  Jee Eun KIM ,  Myungsun KIM

IPC: C12Q1/6827 ,  C12Q1/6886 ,  C12Q1/6874 ,  C12Q1/686 ,  C12Q1/6823

Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.